Norman Wolmark, MD, FACS, FRCSC, will receive the Brinker Award for Scientific Distinction in Clinical Research on Friday, and will deliver the lecture “The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer: PAST AS PROLOGUE.”

Wednesday’s General Session included data from three trials looking at the use of the antibody drug conjugate trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic and HER-2-low, HR-positive early-stage breast cancer.

C. Kent Osborne, MD, opened a session named in his honor on Wednesday as experts discussed the interplay between estrogen receptors and HER2 signaling pathways.

Jeffrey Rosen, PhD, a pioneer of mouse modeling and mouse mammary tumorigenesis, received the William L. McGuire Memorial Lecture Award.

Ruth O’Regan, MD, and Debra Patt, MD, PhD, MBA, will take sides on the impacts of CDK4/6 inhibitors during a Thursday morning debate session.

Nicholas Turner, MD, PhD, will moderate a Thursday afternoon session that will provide an update on the current uses of liquid biopsies in metastatic disease as well as growing applications for ctDNA in clinical trials.

Komal Jhaveri, MD, FACP, will moderate discussions about current controversies in translational medicine for breast cancer.

Seema A. Khan, MD, will lead a session on Thursday afternoon looking at evolving evidence on managing patients at moderate genetic breast cancer risk.